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Structures of P. falciparum PfPK5 Test
the CDK Regulation Paradigm and Suggest
Mechanisms of Small Molecule Inhibition
considerable promise, both because their activities are
most probably essential to parasite survival and be-
cause the overall organization of the cell cycle in malaria
parasites differs considerably from that in mammalian
cells. Available data indicate that these differences re-
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P. falciparum protein kinase 5 (PfPK5) is the best char-Wellcome Centre for Molecular Parasitology
University of Glasgow acterized member of the P. falciparum CDK family. In a
sequence comparison with members of the human CDK56 Dumbarton Road
Glasgow G11 6NU family, it shares the greatest degree of sequence identity
(circa 60%) with human CDK1 and CDK5 (Figure 1A)United Kingdom
(reviewed in Chakrabarti et al., 2002). Maximal PfPK5
protein levels and activity are observed about 30 hr
posterythrocytic infection, at which stage the P. falci-Summary
parum schizont is undergoing multiple rounds of nuclear
division (Graeser et al., 1996). Its localization within thePlasmodium falciparum cell cycle regulators are promis-
ing targets for antimalarial drug design. We have deter- cell and the timing of its activation both strongly suggest
that it plays a role in the regulation of the P. falciparummined the structure of PfPK5, the first structure of a
P. falciparum protein kinase and the first of a cyclin- nuclear division cycle.
In this paper we describe the structure of PfPK5 alonedependent kinase (CDK) not derived from humans. The
fold and the mechanism of inactivation of monomeric and in complex with a set of three ATP-competitive
inhibitors (Table 1). PfPK5 has an inactive fold as a resultCDKs are highly conserved across evolution. ATP-
competitive CDK inhibitors have been developed as of the N-terminal C helix and the activation loop being
in conformations that are incompatible with productivepotential leads for cancer therapeutics. These studies
have identified regions of the CDK active site that can ATP and protein substrate binding. On binding of indiru-
bin-5-sulphonate within the active site cleft, the PfPK5be exploited to achieve significant gains in inhibitor
potency and selectivity. We have cocrystallized PfPK5 C helix moves and adopts a conformation previously
seen in the structure of activated CDK2 (Jeffrey et al.,with three inhibitors that target such regions. The se-
quence differences between PfPK5 and human CDKs 1995). This is the first observation that binding of a small
molecule to a CDK ATP binding site can induce consid-within these inhibitor binding sites suggest that selec-
tive inhibition is an attainable goal. Such compounds erable structural change—in this case similar to that
accompanying cyclin association.will be useful tools for P. falciparum cell cycle studies,
and will provide lead compounds for antimalarial drug
development. Results and Discussion
Structure of PfPK5Introduction
PfPK5 adopts the characteristic bilobate kinase fold
(Figure 1B) (Knighton et al., 1991). The smaller N-terminalPlasmodium falciparum, the protozoan parasite respon-
sible for the lethal form of human malaria, causes around lobe consists of five antiparallel  strands (1–5) and a
single prominent  helix containing the sequence2.0 million deaths every year, mostly among children in
subsaharan Africa. The parasite has developed resis- PSTTIRE that corresponds to the PSTAIRE cyclin bind-
ing motif of CDKs 1, 2, and 3. This lobe is connectedtance against most available antimalarials, making the
through a hinge region to the larger predominantlydiscovery of alternative control agents an urgent task
-helical C-terminal lobe. The PfPK5 structure is the(reviewed in Ridley, 2002). The identification of novel
second determination (the first being that of CDK2 [Dedrug targets has been greatly facilitated by the availabil-
Bondt et al., 1993]) of a structure of a monomeric CDKity of the P. falciparum genomic database (Gardner,
fold. The high degree of sequence identity between2002). Two types of drug target can be identified from
PfPK5 and CDK2 (Figure 1A) is reflected in their struc-the genomic sequence: proteins that are entirely unique
tures, which have an rmsd of 1.3 A˚ calculated over 235to the pathogen, and proteins that can be deduced from
equivalent C atoms. All aspects of the monomericsequence conservation to play an essential role in patho-
CDK2 architecture are well conserved (De Bondt et al.,gen survival (reviewed in Pattanaik et al., 2002).
1993). The two deletions in the PfPK5 sequence (equiva-In this context, Plasmodium cell cycle regulators show
lent to CDK2 residues Lys24 and Ala 93) are both accom-
modated at the apex of  turns, resulting in very little
*Correspondence: jane.endicott@biop.ox.ac.uk
perturbation to the overall structure. The short CDK23 Present address: Watson School of Biological Sciences, Cold
C-terminal tail (residues Val289–Leu298) that wraps to-Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor,
New York. ward the hinge region is absent from PfPK5.
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Figure 1. PfPK5 Sequence and Fold
(A) Alignment of PfPK5 with selected CDKs. PfPK5 (Swissprot accession number Q07785) was aligned with selected CDK sequences (human
CDK2 [P24941], S. pombe Cdc2 [P04551], S. cerevisiae CDC28 [P00546], H. sapien CDK6 [Q00534], H. sapien CDK5 [Q00535], and T. brucei
tbcrk1 [s05853]), using the program CLUSTAL-W (Thompson et al., 1994), and rendered with the program Alscript (Barton, 1993) (numbered
as for PfPK5). Key sequence motifs are highlighted: glycines of the kinase GXGXXG motif, magenta; residues subject to regulatory phosphoryla-
tion in CDK1, red; CDK6 residues that contact p16INK4A, light blue (Russo et al., 1998); residues delineating the activation loop, cyan; residues
equivalent to CDK5 153, a key CDK2/CDK5 sequence difference, salmon (Tarricone et al., 2001); GDSEID motif, involved in both CKS1 (Bourne
et al., 1996) and KAP binding (Song et al., 2001), dark blue; other residues that contact KAP or CKS proteins, turquoise; the kinase insert
region, and CDK insert region, areas of hypervariability between kinases are boxed (Hanks and Hunter, 1995). Residues shaded in yellow are
highly conserved between all CDKs.
(B) The monomeric PfPK5 fold. The N-terminal domain (residues 1–82) is colored white and the C-terminal domain (residues 83–288) gold.
The glycine-rich loop (residues 10–19), the C helix (residues 39–56), and the activation loop (residues 143–170 from the conserved DFG to
APE motifs) are colored magenta, red, and cyan respectively. PfPK5 residues Asp125, Asn130, and Asp143 are drawn in ball-and-stick mode
and are discussed in the main text.
(C) Overlay of the structures of monomeric PfPK5Thr198Ala and CDK2 in the vicinity of the activation loop. CDK2 has been superimposed,
colored green (De Bondt et al., 1993). The CDK2 activation loop forms a  hairpin that turns across the end of the glycine loop, while the
activation loop of PfPK5Thr198Ala adopts an extended structure as it stretches away from L12 into a short  helix of 2.5 turns.
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Table 1. IC50 Values for Selected Inhibitors against CDK2/Cyclin A, CDK4/Cyclin D1, and PfPK5/Cyclin A
IC50 Values (nM)
Inhibitor
CDK2/ PfPK5/ CDK4/
Cyclin A Cyclin A Cyclin D1
Indirubin-3monoxime 440b 6,150g 3330b
Indirubin-3monoxime-5-sulphonate 5f 7,800g NDh
Indirubin-5-sulphonate 35b 5,500g 300b
Staurosporine 7c 1,000g 3,000–10,000d
Purvalanol B 6a 130g 10,000a
NU6102 5e 215g 1,600e
a IC50 values from Gray et al. (1998).
b IC50 values from Hoessel et al. (1999).
c IC50 values from Meijer (1996).
d IC50 values from Meijer (1995).
e IC50 values from Davies et al. (2002).
f IC50 values from Leclerc et al. (2001), value determined against CDK1/cyclin B.
g This paper.
h Not determined.
Conserved residues within the active site, Asp143, PfPK5 crystallizes in an alternative C2 lattice (a 55.3 A˚,
b  94.7 A˚, c  133.2 A˚,   99.2) the activation loopAsp125, and Asn130 (Figure 1B) (equivalent respectively
sequence adopts an -helical structure of 2.5 turns thatto CDK2 residues Asp145, Asp127, and Asn132) are
spans the ATP binding cleft. A buried salt bridge fromsimilarly located in PfPK5 and CDK2. An overlay of the
the catalytic base (Asp125) to a residue of the activationCDK2 and PfPK5 structures shows that the tip of the
loop (Arg155) combines with crystal lattice contacts toPfPK5 glycine loop (residues 10–19, Figure 1B) curls
stabilize this conformation. This structure was first ob-over the active site so that PfPK5 Thr14 clashes with
served for a PfPK5 mutant where Thr198 (a residue re-the ATP -phosphate moiety bound to CDK2. This ob-
mote from the active site) is replaced by an alanineservation may explain the result that PfPK5 crystals
(Table 2, Figure 1C). An equivalent conformation couldgrown in the presence of AMP-PNP in the concentration
not be accommodated within the alternative wild-typerange 1–10 mM have not shown evidence of ATP
PfPK5 crystal lattice. These structures demonstratebinding.
plasticity in the PfPK5 activation loop that allows it toAs previously observed in the structure of monomeric
adopt a novel, ordered conformation that precludes pro-human CDK2 (De Bondt et al., 1993), the disposition of
tein substrate binding.two key structural elements largely explains monomeric
In vitro, PfPK5 is promiscuous in its cyclin bindingPfPK5’s inactivity. The first of these is the C helix (resi-
and can be activated by association with mammaliandues 44–57), which is displaced from the body of the
p25, cyclin H, and cyclin A (the cognate partners respec-protein so that the side chain of Glu50 (the E of the
tively of CDK5, CDK7, and CDK1/2) as well as by aPSTTIRE sequence) points into solvent and does not
putative P. falciparum cyclin Pfcyc-1 (Figure 2A) (seeinteract with Lys32. By analogy with other kinases, it
also Le Roch et al., 2000). By analogy with CDK2, cyclinis expected that these two residues will form a close
binding is likely to induce C helix movement and re-interaction in the active state, that in turn allows Lys32
arrangement of the activation loop to create the ATPto correctly orientate the ATP  and  phosphate groups
binding site, and to promote formation of the protein-for phosphotransfer. That a second member of the CDK
substrate binding site (Jeffrey et al., 1995; Brown et al.,family from a species phylogenetically remote from hu-
1999a). CDK2/cyclin A additionally requires activation
mans adopts this distinctive disposition of the C helix
loop phosphorylation on Thr160 for full activity. Cyclin
provides evidence that the same inappropriate C helix A complexes of wild-type PfPK5 and of a PfPK5 mutant
orientation is employed in the wider CDK family to inhibit where Thr158, the PfPK5 residue equivalent to CDK2
CDK activity. Thr160, is mutated to an alanine show similar levels of
The second regulatory structural element is the activa- activity indicating that activation loop phosphorylation
tion loop (residues 143–170 between and including the is not a prerequisite for PfPK5 activity (Figure 2A). How-
conserved DFG and APE/D motifs) that contributes to ever, we cannot exclude the possibility that the levels
the substrate binding site (Brown et al., 1999a). The of PfPK5/cyclin A activity that we measure do not repre-
activation loop of monomeric CDK2 has been reported sent the in vivo activity of a cognate cyclin-bound PfPK5
to be either disordered (Brown et al., 1999b) or to adopt in the presence of an activating kinase. By analogy with
a conformation that precludes the binding of protein the reported interaction of CDK6 with K-cyclin (Schulze-
substrate but not ATP (De Bondt et al., 1993) (Figure Gahmen and Kim, 2002) it is also possible that the au-
1C). Wild-type apo-PfPK5 can also adopt either a disor- thentic phosphorylation dependence of PfPK5 activity
dered or ordered activation loop structure dependent is removed by binding to a noncognate cyclin. PfPK5 is
on the crystal form. In crystals that are in C2, a 222.1 A˚, not phosphorylated by S. cerevisiae Cak1p or by com-
b  44.3 A˚, c  63.0 A˚,   103.4 (Table 2), the electron plexes of either human or X. laevis CDK7/cyclin H under
density maps indicate a disordered activation loop conditions where these enzymes are able to phosphory-
late monomeric CDK2 on Thr160 (Figure 2B).structure between residues 152 and 160. However, when
Structure
1332
Table 2. Crystallographic Data and Refinement Statistics
Monomeric Monomeric PfPK5/ PfPK5/Indirubin- PfPK5 Thr198Ala
PfPK5 PfPK5 PfPK5/NU6102 PurvalanolB 5-Sulphonate Mutant
Cell dimensions (A˚) 222.1, 44.3, 63.0 88.0, 119.3, 63.3 62.3, 88.3, 121.6 222.6, 44.4, 63.8 60.6, 88.3, 63.9 55.3, 94.7, 133.2
  103.4   103.2   97.3   99.2
Space group C2 P21212 P2221 C2 P21 C2
Maximal resolution (A˚) 1.90 2.80 3.00 2.00 1.90 2.20
Observations 120,555 62,835 48,195 90,226 92,624 76,044
Unique reflections, 46,965 (99.0) 16,952 (99.7) 13,660 (97.8) 38,513 (93.1) 49,359 (94.1) 33,495 (97.0)
completeness (%)
Rsyma 0.094 0.078 0.065 0.093 0.150 0.098
Mean I/(I) 4.3 6.9 8.3 4.4 2.2 5.6
Highest resolution 2.00–1.90 2.90–2.80 3.16–3.00 2.11–2.00 2.00–1.90 2.42–2.20
bin (A˚)
Completeness (%) 97.9 99.6 94.9 71.0 94.5 99.0
Mean I/mean (I) 1.6 1.9 2.0 1.6 1.9 1.5
Rsyma 0.414 0.385 0.390 0.461 0.277 0.393
Protein residues
Chain A residues 1–151, 161–286 2–37, 43–151, 1–151, 160–286 3–36, 44–286 1–286
161–286
Chain B residues 2–32, 44–71, 2–37, 43–150, 2–32, 44–150, 3–36, 47–286 3–34, 48–151,
75–150, 164–286 164–286 164–286 162–286
Other atom 329 water 2 molecules of 2 molecules of 2 molecules of 326 water
NU6102 purvalanol B Indirubin-5- molecules
sulphonate
243 water 258 water
molecules molecules
Resolution range (A˚) 36.2–1.9 21.7–3.0 28.5–2.0 25.0–1.9 27.0–2.2
Rconvb 0.19 0.23 0.20 0.23 0.22
Rfreec 0.22 0.30 0.27 0.28 0.28
Mean protein temperature factors (A˚)2
Main chain 36.0 66.7 36.4 32.0 35.1
Side chain 40.0 70.5 39.4 32.3 38.5
Mean ligand tempera- — 77.6 42.1 28.0 —
ture factors (A˚)2
a Rsym  	h	j|Ih,j 
 Ih|/	h	jIh,j, where Ih,j is the intensity of the jth observation of unique reflection h.
b Rconv  	h|Foh| 
 |Fch|/	h|Foh|, where Foh and Fch are the observed and calculated structure factor amplitudes for reflection h.
c Rfree is equivalent to Rconv but is calculated using a 5% disjoint set of reflections excluded from the maximum likelihood refinement stages.
PfPK5 Sequence Conservation conserved in PfPK5, suggests either that a putative plas-
modial CKS does not have a conserved CDK bindingThe molecular surfaces presented by PfPK5 and CDK2
differ markedly as most of the conserved residues are site or that P. falciparum does not have such a protein.
It is difficult to distinguish between these two alterna-within the protein core (Figure 3). In particular, two se-
quences of kinase hypervariability, the kinase insert re- tives by relying on sequence data from phylogenetically
divergent organisms.gion (KIR) and the CDK-insert region (CIR) (Figure 1A),
are different in the two proteins. These regions encode
respectively the loops that precede E and G. X-ray PfPK5/ATP-Competitive Inhibitor Complexes
Structure-lead inhibitor design and SAR analysis of mul-crystallographic studies have shown that this surface
contributes to the CDK2 CKS1 (Bourne et al., 1996) (Fig- tiple CDK inhibitor series have led to the development
of a pharmacophore model of the CDK ATP binding siteure 3), and kinase-associated phosphatase (KAP) (Song
et al., 2001) binding sites. The pattern of sequence con- (reviewed in Fabbro et al., 2002; Fischer et al., 2002).
We have cocrystallized PfPK5 with three inhibitors thatservation between PfPK5 and CDK2 within the CDK2
cyclin A binding site shows that although the peripheral target regions shown to mediate inhibitor potency and
selectivity. A comparison of the IC50 values shows thatresidues differ, the PfPK5 molecular surface does re-
semble that of CDK2 within its core (Figure 3). This ob- CDK2/cyclin A and PfPK5/cyclin A differ significantly in
their susceptibility to inhibition by these compoundsservation supports the result that cyclin A can activate
PfPK5 in vitro. As judged from size exclusion chroma- (Table 1). Although the smaller purine-based inhibitors
are potent at nanomolar concentrations against bothtography, PfPK5 does not form a stable complex with
bovine cyclin A3 or human CKS1 under conditions where kinases, the larger inhibitors, staurosporine, and the in-
dirubin derivatives, are much less active against PfPK5.CDK2 stably associates with each of these proteins
(data not shown). Together with the structures presented below, these
results suggest that the PfPK5 binding site can be tar-Extensive searching of the P. falciparum genome has
failed to identify a CKS homolog (C.D., unpublished geted for the development of PfPK5 selective small mol-
ecule inhibitors.data). This result, together with our structural analysis
that shows that the CDK2 CKS binding surface is not 6-cyclohexylmethoxy-2-(4-sulfamoylanilino)purine
P. falciparum Protein Kinase 5
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Figure 2. Phosphorylation and Kinase Activity of PfPK5
(A) PfPK5 histone H1 kinase activity. 15 pmol of PfPK5WT or PfPK5T158A protein were preincubated at 30C for 30 min either alone (lanes 1 and
3) or with 15 pmol of bovine cyclinA3 (lanes 2 and 4). After the addition of 0.5 g histone H1, 0.1 mM ATP, 1 Ci [32P]ATP, 15 mM MgCl2, 2
mM MnCl2, and 25 mM Tris-HCl, pH 7.4, samples were incubated for a further 30 min at 30C. The final reaction volume was 10 l. Reactions
were stopped by the addition of loading dye, and analyzed on a 12% Tris-glycine SDS-PAGE and then by autoradiography. Lanes 5 and 6
are negative controls. Results are discussed in the main text.
(B) Phosphorylation of the PfPK5 activation segment. 15 pmol of substrate (either CDK2 or PfPK5) was incubated with 2 pmol of enzyme
(human CDK7/CyclinH, X. laevis CDK7/CyclinH, or S. cerevisiae GST-CIV1, all kind gifts of Dr. N. Brown) for 30 min at 30C. Reaction buffer
was 0.1 mM ATP, 1 Ci [32P] ATP, 15 mM MgCl2, 2 mM MnCl2, and 25 mM Tris-HCl, pH 7.5. Reactions were stopped by addition of loading
dye and then analyzed by SDS-PAGE and autoradiography. All CAKs phosphorylate CDK2 with differing efficacy (lanes 2–4), but do not
phosphorylate PfPK5 (lanes 6–8). CDK2 and PfPK5 do not autophosphorylate under these conditions (lanes 1 and 5).
(NU6102) (Davies et al., 2002) and purvalanol B (Gray et poses the C2 R-isopropyl group to make van der Waals
contacts with Gly11, Glu12, Gly13, and Val18 from theal., 1998) are trisubstituted purines that bind in distinct
orientations within the ATP binding site. Each inhibitor kinase glycine-rich loop (Figure 4A). However, it should
be noted that extensive SAR analyses against CDK2 tomakes a triplet of hydrogen bonds between its purine
backbone atoms and PfPK5 backbone amide and car- probe this site in a number of inhibitor series have shown
that it is a difficult interaction to target for gains in po-bonyl groups within the hinge region (Figure 4A). The
purine rings are sandwiched within the cleft and make tency, presumably because of intrinsic flexibility (Gibson
et al., 2002; reviewed in Fischer et al., 2002). Notably,a number of van der Waals and hydrophobic contacts
with residues Ile10, Val18, Ala30, Phe79, and Leu132. this flexibility is also a feature of the PfPK5 glycine loop
as revealed by the high B factor values associated withThe isopropyl group at N9 of purvalanol B makes hy-
drophobic interactions with Phe79 while the purine ring this region in the PfPK5/ NU6102 structure.
The successful exploitation of potential interactionsof NU6102 makes a direct edge-face aromatic-aromatic
contact with this residue. with the CDK2 C-terminal domain has lead to the devel-
opment of a number of potent CDK2 inhibitors that showBoth inhibitors place small side chains within the ATP
ribose-phosphate binding site which, in their interac- good selectivity between CDK1/2 and CDK4/6 (Gray et
al., 1998; reviewed in Fischer et al., 2002). In agreementtions with PfPK5, mimic those previously reported with
CDK2 (Gray et al., 1998; Davies et al., 2002). The C2 with previous studies on CDK2, the anilino rings of pur-
valanol B and NU6102 that probe this region are nothydroxyl group of purvalanol B makes a hydrogen bond
with the backbone carbonyl group of Gln129 that dis- coplanar when bound to PfPK5 (Figure 4A). The purvala-
Structure
1334
Figure 3. Comparative Analysis of Sequence
Conservation between PfPK5 and CDK2 and
Known Sites of CDK2-Protein Interaction
The structures of complexes of T160-phos-
phorylated CDK2/cyclin A/AMP-PNP/sub-
strate peptide (Brown et al., 1999a) and
CDK2/CKS1 (Bourne et al., 1996) were super-
imposed within the program O (Jones et al.,
1991). AMP-PNP and the substrate peptide
(sequence HHASPRK) are drawn in ball-and-
stick mode with carbon atoms colored green.
CKS1 and cyclin A are rendered in ribbon
representation and colored dark purple and
green respectively. The CDK2 molecular sur-
face is colored cyan for those residues where
the CDK2 and PfPK5 sequences are similar
in character as defined by a score greater
than 0 in the Blosum65 matrix (Henikoff and
Henikoff, 1992) or red where the pair score is
less than or equal to 0. The view in (A) is
similar to that in Figures 1B and (B) is rotated
around the y axis.
nol B N6 chlorocarboxyanilino ring adopts a single con- This conformation resembles one of the two conforma-
tions observed for this group when it is bound to mono-formation that allows for -stacking interactions with
the PfPK5 backbone at residue Gln84, and a hydrogen meric CDK2. NU6102 makes hydrogen bonds between
the sulfamoyl group and the side chain and backbonebond between the chlorine atom and the sidechain of
Asp85. The carboxylate function is directed into solvent. amide of Asp85 (Figure 4A).
Figure 4. Inhibitor Binding to PfPK5
(A) Stereo pair of NU6102 and purvalanol B bound within the PfPK5 active site. All residues in the PfPK5 structure bound to NU6102 within
a 7 A˚ sphere of the inhibitor are drawn. The inhibitor and PfPK5 structures are drawn in ball-and-stick mode with carbon atoms of PfPK5,
NU6102, and Purvalanol B colored white, yellow, and cyan respectively. To illustrate the minor differences between the PfPK5 structures in
the glycine loop and at residue Lys88, residues Ile10 and Lys88 from the PfPK5/Purvalanol B structure have also been drawn with carbon
atoms colored white. Hydrogen bonds between the NU6102 sulfamoyl substituent and PfPK5 are shown as dotted lines.
(B) Sequence differences between CDK1, CDK2, CDK4/6, and PfPK5 close to the ATP nucleotide binding site.
P. falciparum Protein Kinase 5
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Figure 5. Indirubin-5-Sulphonate Binding to
PfPK5
Stereo pair. The structures of monomeric
PfPK5 (magenta), T160-phosphorylated CDK2/
cyclin A (gold/green), and PfPK5/indirubin-
5-sulphonate (cyan) were superimposed as
described and rendered in ribbon representa-
tion. The side chains of PfPK5 residues
Lys32, Glu50, and Asp143 and indirubin-
5-sulphonate are drawn in ball-and-stick
mode with carbon atoms colored cyan and
green respectively. Model phased 2Fobs-
Fcalc·calc electron density for the inhibitor is
contoured at 0.2 e
A˚
3. The view highlights
the different orientations of the C helix relative
to the rest of the PfPK5 fold in the PfPK5 and
PfPK5/indirubin-5-sulphonate structures.
Purvalanol B and NU6102 were optimized as CDK2- The structures presented here characterize the PfPK5
binding modes of representatives from chemically di-selective inhibitors through respectively either cycles
of iterative chemical library synthesis and biological verse series of CDK inhibitors. Each series has been
the subject of extensive SAR analysis to identify keyscreening (Gray et al., 1998) or structure-lead design
(Davies et al., 2002). Many of the residues that they interactions involved in their potency and specificity. By
evaluating those analyses in the context of the PfPK5contact are conserved in PfPK5 and as a result they are
good lead-compounds for inhibitor design against this inhibitor structures, we hope to be able to identify suit-
able modifications for our lead compounds to providekinase (Table 1). PfPK5 has significant sequence differ-
ences from members of the human CDK family in the the desired properties of potency and selectivity against
PfPK5.residues that lie adjacent to the ATP binding site within
the C-terminal domain (Figure 4B). The sequence differ- Unexpectedly, the structure of PfPK5 in complex with
indirubin 5-sulphonate resembles that of CDK2 in itsences between CDK2 and CDK4/6 in this region are
sufficient to explain the majority of selectivity displayed active, cyclin A-bound conformation, particularly in re-
spect of the orientation of the C helix (Brown et al.,by various CDK2 or CDK4-selective inhibitors (Gray et
al., 1998; Ikuta et al., 2001; Davies et al., 2002). PfPK5 1999a; Jeffrey et al., 1995). In addition, the C-terminal
end of the activation loop is ordered into a novel confor-is as far diverged from CDK2 and CDK4/6 in this region
as are the two human CDKs from each other, suggesting mation that most closely resembles that observed in
activated CDK2. This observation raises the intriguingthat PfPK5 selectivity, at least with respect to human
CDKs, could be achieved by probing this site. possibility that the inhibitor-bound conformation affords
an approximate view of the activated form of PfPK5. IfThe binding of indirubin-5-sulphonate to PfPK5 sub-
stantially rearranges the PfPK5 ATP binding site (Figure so, further aspects of the structure-function relationship
that underlies CDK regulation, namely the active confor-5). The C helix moves significantly to bring the side chain
of Glu50 (equivalent to CDK2 Glu51) into the ATP binding mation of the C helix and of the C-terminal end of the
activation loop, are conserved across evolution.site, where it interacts with the -amino group of Lys32
(equivalent to CDK2 Lys33), and the 5-sulphonate group
of the inhibitor. The sulphonate group therefore mimics Experimental Procedures
the interactions of the ATP -phosphate group bound
PfPK5 Expression, Purification, and Crystallizationto CDK2/cyclin A. To accommodate the movement of
Optimal expression of PfPK5 (accession number X61921) clonedthe C helix, the PfPK5 L12 helix has melted to form a
into the vector pGEX6P-1 (APB) was observed in BL21-CodonPlusshort  strand, a conformational change that might be
(RIL) cells (Stratagene, La Jolla, CA) following overnight induction
prompted by the reorientation of the side chain of Asp143. at 20C with a final concentration of 0.1 mM IPTG. Cell pellets (0.5
This side chain also forms a close contact (4.3 A˚) with liter E.coli cells) were resuspended in buffer A (40 mM HEPES, pH
7.5, 300 mM NaCl, 0.02% monothioglycerol [MTG]) and lysed bythe inhibitor sulphonate group (Figure 5).
sonication. PfPK5 was purified from the soluble fraction by glutathi-The major reorganization in response to the binding
one affinity chromatography followed by digestion with 3C proteaseof indirubin 5-sulphonate demonstrates that PfPK5, like
and a final size exclusion chromatography (Pharmacia Superdex75other protein kinases, can be subject to large conforma-
HiLoad 26/60) step. Final yields of PfPK5 ranged between 3 and 6
tional change in response to inhibitor binding (Schindler mg/l E. coli culture. Protein was routinely concentrated to 14 mg/
et al., 2000; Regan et al., 2002). Although inhibitors have ml using Amicon ultracentrifuge concentrators, flash frozen in liquid
nitrogen, and stored at 
80C. Freeze thawing was not detrimentalbeen shown to modify the structure of monomeric CDK2
to enzymatic activity. Monomeric PfPK5 crystals were grown at 4C(e.g., Lawrie et al., 1997; Hoessel et al., 1999), the ob-
using the hanging drop method by mixing equal volumes (1 l) ofserved structural changes were relatively subtle. The
PfPK5 (9 mg/ml in buffer A modified to 200 mM NaCl) and wellbiological significance of this apparent difference in flex-
solution (100 mM HEPES sodium salt adjusted to pH 7.5 with acetic
ibility remains to be established, but it may be a charac- acid, 10 mM MgCl2, PEG 8K [8%–16%], isopropanol [2%–8%]).
teristic that can be exploited in the development of spe- The PfPK5/NU6102 dataset was collected from a crystal soaked
for 30 min at room temperature in 1 mM NU6102 in 1mother liquorcific inhibitors.
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